Scilex Holding Company

What Scilex Holding Company does

Scilex Holding Company (Nasdaq: SCLX) is a Palo Alto-based specialty pharmaceutical company that acquires, develops, and commercializes non-opioid prescription products for acute and chronic pain. Its commercial portfolio consists of three FDA-approved products approved via the 505(b)(2) pathway: ZTlido® (lidocaine topical system 1.8%) for post-herpetic neuralgia, launched October 2018; Elyxyb® (celecoxib oral solution) for acute migraine, launched April 2023; and Gloperba® (colchicine oral solution) for gout flare prophylaxis, launched June 10, 2024. The platform rests on proprietary delivery technologies: an anhydrous, single-layer, drug-in-adhesive topical patch system, proprietary liquid oral solution formulations for colchicine and celecoxib, and a viscous gel formulation for epidural corticosteroids (SP-102/SEMDEXA). Three pipeline candidates are in development — SP-102 (Phase 3, FDA Fast Track), SP-103 (Phase 2, Fast Track in low back pain), and SP-104 (Phase 1 for fibromyalgia) — together with a joint venture (Scilex Bio) advancing the KDS2010 MAO-B inhibitor for obesity and neurodegenerative disease.

The business model combines branded prescription product sales in the U.S. (distributed through AmerisourceBergen, Cardinal Health, McKesson, and Endeavor Distribution) with international licensing partnerships (Itochu and Oishi Koseido for Japan; Tamer Group and AD Ports Group for the Middle East; Dr. Reddy's for India). ZTlido is cited as the #1 prescribed non-opioid branded analgesic among pain specialists per Symphony Rx data (Jan-Nov 2023), with over 1 million patients treated since launch. Scilex has been an unusually active capital raiser, completing multiple post-IPO equity offerings, convertible note financings, and debt facilities (including a $100M 5-year facility from Perigrove/Graf Holdings and a non-recourse $50M facility from The St. James Bank), and has also deployed significant capital as a strategic investor — most notably a $150M investment in Datavault AI (NASDAQ:DVLT) giving it a ~37–40% stake, plus a $120M contribution toward a 100-city quantum-ready GPU edge network, and a $10M worldwide exclusive license to Datavault AI's biotech tokenization technology with up to $2.55 billion in contingent milestone payments.

Scilex became public in November 2022 via reverse merger with Vickers Vantage Corp. I and operates through wholly-owned subsidiaries Scilex Pharmaceuticals and Semnur Pharmaceuticals (acquired March 2019). Recent corporate activity extends well beyond traditional pharma into strategic crypto/digital-asset and AI-adjacent investments: Scilex paid the $150M Datavault AI investment in Bitcoin, holds ~1,237.6 Bitcoin on Datavault's balance sheet, and is distributing meme coin tokens (Dream Bowl I) and the Semnur common stock as dividends to shareholders. The company is also engaged in active securities litigation (filed March 11, 2026 in the Central District of California) against The St. James Bank & Trust, Omega & Corinth, and BNY Mellon seeking recovery of approximately 96 million pledged Datavault AI shares and damages exceeding $100 million.

Name

Scilex Holding Company

Legal name

Scilex Holding Company

Website

https://scilexholding.com

Company type

Public

Founded year

2022

Operating status

Operating

Headcount range

101–250 employees

Short description

Scilex Holding Company (Nasdaq: SCLX) is a Palo Alto-based specialty pharmaceutical firm that develops and commercializes FDA-approved non-opioid pain and specialty prescription products (ZTlido®, Gloperba®, Elyxyb®) and a pipeline of late-stage candidates, serving pain specialists and patients in the U.S. and through international licensing partners.

Ownership category

akta.pro rank

Product category

Non-Opioid Pain Management Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

akta.pro secondary industries

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK), Headache & Migraine Medicine (HLAKAIAE), Pain Relief & Anti-Inflammatory (Analgesics) (HLAIADAA), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Non-opioid pain management
• Topical drug delivery
• Specialty pharmaceuticals
• Prescription pain therapeutics
• Transdermal pharmaceutical patches

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Marketing or Sales, Personnel, Supply Chain, Operations

Revenue model

1. Branded Pharmaceutical Product Sales: Revenue from sales of FDA-approved non-opioid pain management products ZTlido® (launched October 2018), Gloperba® (launched June 10, 2024), and Elyxyb® (launched April 2023). ZTLido cited as #1 prescribed non-opioid branded analgesic among pain specialists with >1 million patients treated.
2. International Licensing & Distribution Revenue: In-licensed U.S. rights for Gloperba in 2022 and U.S./Canada rights for Elyxyb in February 2023. International commercialization through partner network (Itochu, Oishi Koseido, Tamer Group, AD Ports Group).
3. Biotech Tokenization Licensing Revenue (Datavault AI license): $10 million worldwide exclusive license agreement with Datavault AI for tokenization and monetization of biotech assets (genomic, DNA, diagnostic, therapeutic, drug data) - paid in four quarterly $2.5M installments through September 2026, plus up to $2.55 billion in contingent sales milestone payments.
4. Strategic Investment Revenue Participation: $120 million cash contribution to Datavault AI in exchange for tiered revenue participation from quantum-ready GPU edge network (30% of gross revenues until $250M, then 15% until $1.2B, then 5% thereafter).
5. Strategic Equity Investment Income: Major shareholder (~37-40% stake) in Datavault AI Inc. (NASDAQ:DVLT) acquired via $150 million investment; Bitcoin-related investments contributing to investment portfolio appreciation.

Pricing tiers

Go-to-market motion1 record

Distribution channels12 records

Marketing channels9 records

Core offering

Scilex Holding Company acquires, develops, and commercializes FDA-approved non-opioid prescription pharmaceutical products for acute and chronic pain management, with three commercial products (ZTlido® lidocaine topical system 1.8% for post-herpetic neuralgia, Gloperba® colchicine oral solution for gout flare prophylaxis, and Elyxyb® celecoxib oral solution for acute migraine) supported by a pipeline of three product candidates and a joint-venture MAO-B inhibitor program. The company leverages proprietary drug-delivery technology — including an anhydrous single-layer topical patch platform and proprietary liquid oral formulations — and markets through major U.S. wholesalers and a specialty sales force.

Product overview

Scilex Holding Company (Nasdaq: SCLX) is a revenue-generating specialty pharmaceutical company with a platform-plus-portfolio architecture centered on three FDA-approved non-opioid pain management commercial products — ZTlido® (lidocaine topical system 1.8%) for post-herpetic neuralgia, GLOPERBA® (colchicine USP oral solution) for gout flare prophylaxis, and ELYXYB® (celecoxib oral solution) for acute migraine — supported by a pipeline of three product candidates: SP-102/SEMDEXA™ (epidural dexamethasone gel for sciatica, Phase 3), SP-103 (triple-strength lidocaine topical system for chronic neck pain, Phase 2), and SP-104 (low-dose naltrexone for fibromyalgia, Phase 1). The platform rests on proprietary anhydrous, single-layer, drug-in-adhesive topical delivery technology used to optimize adhesion and drug penetration. Scilex Pharmaceuticals and Semnur Pharmaceuticals are wholly-owned subsidiaries, and the company has formed a separate joint venture, Scilex Bio, to advance the MAO-B inhibitor KDS2010 for obesity and neurodegenerative diseases.

Differentiator

Problem solved

Functional benefit

Brands

• ZTlido®: FDA-approved prescription lidocaine topical system 1.8% for the relief of pain associated with post-herpetic neuralgia (PHN), a form of post-shingles nerve pain; proprietary adhesion/delivery technology.
• Elyxyb®
• Gloperba®
• SEMDEXA™ (SP-102)

Products and services

• ZTlido® (lidocaine topical system 1.8%) FDA-approved prescription lidocaine topical product for the relief of pain associated with Post-Herpetic Neuralgia (PHN), a form of post-shingles nerve pain. Uses Scilex's proprietary anhydrous, single-layer, drug-in-adhesive topical delivery system designed to provide significantly improved adhesion and continuous pain relief. Approved via 505(b)(2) pathway and launched in the U.S. in October 2018.
• GLOPERBA® (colchicine USP) oral solution FDA-approved first and only liquid oral version of the anti-gout medicine colchicine, indicated for the prophylaxis of painful gout flares in adults. Enables individualized precision dosing in high-risk patients. U.S. rights in-licensed by Scilex in 2022; launched in the U.S. on June 10, 2024 via 505(b)(2) pathway.
• ELYXYB® (celecoxib oral solution) FDA-approved oral solution of celecoxib indicated for the acute treatment of migraine with or without aura in adults. The only liquid ready-to-use analgesic formulated in a proprietary delivery system, designed to deliver fast and long-lasting migraine relief. U.S. and Canada rights in-licensed in February 2023; launched in the U.S. in April 2023 via 505(b)(2) pathway.

Quantifiable outcome

• Over 1 million patients treated with ZTlido since launch
• +7 more outcomes

Named customers1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

20 partnerships are on record, tiered flagship, major, core and minor.

• Datavault AI Inc. & Wellgistics Health (DelivMeds AI)flagshipStrategic or Co-development Partner · 20 May 2026Three concurrent transactions for DelivMeds AI (~$4 billion combined asset value): expansion of PharmacyChain license to include Healthcare-as-a-Service IP, acquisition of QOLPOM biometric and drone logistics IP from EOS Technology Holdings and Scilex Holding Company, and acquisition of controlling stake in Tollo Health. North Carolina pilot planned for July 2026; national rollout at Pro Football Hall of Fame Game August 2026.
• Datavault AI Inc.flagshipStrategic or Co-development Partner · 27 April 2026Binding term sheet for $120 million cash contribution from Scilex to fund deployment of quantum-ready GPU edge network across approximately 100 U.S. cities. Scilex receives 30% of network revenues until $250M paid, 15% until $1.2B total, and 5% thereafter. Initial deployments in New York and Philadelphia expected Q2 2026; full 100-city coverage within 36 months. Combined with Nvidia GPU inventory valued at $1.2B, projects $200M-plus cash infusion without equity dilution.
• Quantum Scan Holdings, Inc.majorStrategic or Co-development Partner · 1 February 2026$20 million strategic investment targeting trillion-dollar preventive diagnosis and prognosis markets. Supports Quantum Scan's development of advanced diagnostic platforms, integrated analytics, and scalable healthcare solutions. Complements Scilex's prior investment in Datavault AI.
• Datavault AI Inc.flagshipStrategic or Co-development Partner · 4 November 2025$10 million worldwide exclusive license agreement granting Scilex rights to sublicense Datavault AI's AI-driven technology for building a Biotech Exchange platform to tokenize and monetize genomic, DNA, diagnostic, therapeutic, and drug data assets. Payment in four quarterly $2.5M installments through September 2026, plus up to $2.55 billion in contingent sales milestone payments. Targets an estimated $2.0 trillion opportunity in pharmaceutical and diagnostic asset tokenization.
• IPMC Company (Bio Innovation Consortium/BOIC) and NeuroBiogen CompanymajorStrategic or Co-development Partner · 1 February 2024Joint venture Scilex Bio formed with IPMC Company (representative of BOIC), which holds exclusive rights to NeuroBiogen Company's KDS2010 global license. JV will develop and commercialize next-generation reversible MAO-B Inhibitor for obesity and neurodegenerative diseases including Alzheimer's disease.
• Vickers Vantage Corp. I (OTCMKTS:VCKAU)flagshipStrategic or Co-development Partner · 1 November 2022Reverse merger with Vickers Vantage Corp. I (Singapore-based SPAC) in November 2022 enabled Scilex to become publicly listed on NASDAQ under ticker SCLX.
• Semnur Pharmaceuticals, Inc.flagshipStrategic or Co-development PartnerWholly-owned subsidiary of Scilex Holding Company; subject of dividend distribution of Semnur common stock to Scilex stockholders with payment date confirmed as June 15, 2026.
• AmerisourceBergencoreChannel Partner/ Reseller/ DistributorMajor U.S. pharmaceutical distribution partner for Scilex's branded pharmaceutical products (amerisourcebergen.com).
• Cardinal HealthcoreChannel Partner/ Reseller/ DistributorMajor U.S. pharmaceutical distribution and biopharmaceutical drug development/regulatory services partner (cardinalhealth.com).
• McKessoncoreChannel Partner/ Reseller/ DistributorMajor U.S. pharmaceutical distribution partner (mckesson.com).
• Endeavor DistributionminorChannel Partner/ Reseller/ DistributorPharmaceutical distribution partner (endeavordistribution.com).
• Itochu Chemical Frontier Co., Ltd.minorChannel Partner/ Reseller/ DistributorInternational commercialization partner for Japanese market (itcchem.co.jp).
• Oishi Koseido Co., Ltd.minorChannel Partner/ Reseller/ DistributorInternational commercialization partner for Japanese market (o-koseido.co.jp).
• Tamer GroupminorChannel Partner/ Reseller/ DistributorInternational pharmaceutical distribution partner for Middle East market (tamergroup.com).
• AD Ports GroupminorChannel Partner/ Reseller/ DistributorInternational distribution partner for UAE market (adportsgroup.com).
• Dr. Reddy's LaboratoriesminorChannel Partner/ Reseller/ DistributorListed as international pharmaceutical partner (drreddys.com).
• ROMEG (Rx Optimization & Management Exchange Group)minorChannel Partner/ Reseller/ DistributorDistribution partner (romegrx.com).
• CH GroupminorChannel Partner/ Reseller/ DistributorU.S. distribution partner (chgroupus.com).
• Aardvark TherapeuticsminorStrategic or Co-development PartnerListed as partner (aardvarktherapeutics.com).
• NeuroBiogen CompanyminorStrategic or Co-development PartnerListed as partner (neurobiogen.com); holds the KDS2010 global license used in Scilex Bio joint venture.

Scale indicators18 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Collegium Pharmaceutical: Specialty pharmaceutical company focused on responsible pain management with a portfolio of non-opioid and abuse-deterrent products including Xtampza ER. Directly comparable as a U.S.-listed specialty pharma commercializing pain therapeutics to similar physician specialties.
• Pacira BioSciences: Specialty pharma company focused on non-opioid pain management with EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic. Comparable as a non-opioid pain franchise targeting the same physician prescriber base and addressing similar regulatory and reimbursement dynamics.
• Assertio Therapeutics: Specialty pharmaceutical company focused on non-opioid pain and neurology products including INDOCIN and OXAYDO. Comparable in commercial-stage pain management with a similar specialty pharmaceutical sales force and product portfolio approach.
• BioDelivery Sciences International: Specialty pharmaceutical company focused on pain management and addiction medicine with products like BELBUCA (buprenorphine buccal film). Comparable as a small-cap specialty pharma commercializing pain therapeutics to similar prescriber audiences.

Emerging players

• Cara Therapeutics: Clinical-stage biopharmaceutical company developing novel peripherally acting kappa opioid receptor agonists for pruritus and pain. Comparable in non-opioid pain therapeutics development, with overlapping focus on reducing opioid reliance.
• Tonix Pharmaceuticals: Clinical-stage pharmaceutical company developing treatments for central nervous system disorders including pain and fibromyalgia (similar to Scilex's SP-104 indication). Comparable as a small-cap pharma with multiple specialty product candidates.

Broad incumbents

• Endo International: Large specialty pharmaceutical company with broad pain management portfolio including both opioid and non-opioid products. Comparable as a competitor in the pain management space, though significantly larger with broader product portfolio.
• Teva Pharmaceutical Industries: Global pharmaceutical company with significant pain management portfolio including lidocaine patches and migraine therapeutics. Comparable as a competitor in non-opioid pain with greater resources and global reach.
• Vertex Pharmaceuticals: Large pharmaceutical company that recently launched Journavx (suzetrigine), a first-in-class non-opioid pain signal inhibitor for acute pain. Comparable in advancing non-opioid pain therapeutics to address the opioid crisis.
• Pfizer: Large global pharmaceutical company with extensive pain management portfolio including Celebrex (celecoxib), Lyrica, and other pain therapeutics. Comparable through Scilex's Elyxyb (celecoxib oral solution) competing with Pfizer's celecoxib franchise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/scilex.pharm
• LinkedInlinkedin.com/company/scilex-holding-company

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries3 records

Funding overview

Funding rounds11 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments7 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Scilex Holding Company